Investors purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Friday. $331.19 million flowed into the stock on the tick-up and $102.03 million flowed out of the stock on the tick-down, for a money net flow of $229.16 million into the stock. Of all stocks tracked, Johnson & Johnson had the 3rd highest net in-flow for the day. Johnson & Johnson traded down ($0.18) for the day and closed at $123.00

Several equities research analysts recently weighed in on JNJ shares. Argus upped their price objective on shares of Johnson & Johnson from $116.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, April 20th. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 20th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Sunday, April 17th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, April 19th. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 6th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $112.77.

The stock has a market cap of $338.33 billion and a PE ratio of 22.42. The company has a 50-day moving average price of $118.11 and a 200-day moving average price of $109.60.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.65 by $0.03. The firm earned $17.50 billion during the quarter, compared to analyst estimates of $17.50 billion. During the same quarter in the previous year, the business earned $1.56 earnings per share. Johnson & Johnson’s revenue for the quarter was up .6% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post $6.61 EPS for the current fiscal year.

In other Johnson & Johnson news, VP Gary J. Pruden sold 9,735 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the transaction, the vice president now owns 43,630 shares in the company, valued at $5,062,388.90. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $115.79, for a total value of $347,370.00. Following the transaction, the chief accounting officer now owns 28,725 shares in the company, valued at approximately $3,326,067.75. The disclosure for this sale can be found here.

Other institutional investors recently modified their holdings of the company. Heritage Wealth Advisors boosted its position in shares of Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock worth $1,021,000 after buying an additional 317 shares during the period. S. R. Schill & Associates boosted its position in shares of Johnson & Johnson by 122.7% in the fourth quarter. S. R. Schill & Associates now owns 11,110 shares of the company’s stock worth $1,141,000 after buying an additional 6,121 shares during the period. Lourd Capital LLC boosted its position in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock worth $1,142,000 after buying an additional 851 shares during the period. Eidelman Virant Capital boosted its position in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock worth $1,193,000 after buying an additional 1,231 shares during the period. Finally, Vigilant Capital Management LLC boosted its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. Vigilant Capital Management LLC now owns 11,838 shares of the company’s stock worth $1,216,000 after buying an additional 210 shares during the period.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.